- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| Di | JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target | 6 | Investing.com | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Di | JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential | 15 | Investing.com | ||
| 13.11. | Vor Biopharma: Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 314 | GlobeNewswire (Europe) | Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected... ► Artikel lesen | |
| 12.11. | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | Vor Biopharma Stock Sinks 48% | 9 | RTTNews | ||
| 11.11. | Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial | 12 | Benzinga.com | ||
| 11.11. | Vor Biopharma slumps 26%, prices $100M equity at $10 per share | 1 | Seeking Alpha | ||
| 11.11. | Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr | 3 | RTTNews | ||
| 11.11. | Vor Bio prices $100 million public offering of common stock | 6 | Investing.com | ||
| 11.11. | Vor Biopharma: Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock | 195 | GlobeNewswire (Europe) | BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the... ► Artikel lesen | |
| 10.11. | Vor Bio launches $100 million common stock offering | 1 | Investing.com | ||
| 10.11. | Vor Bio launches $100M public stock offering | 2 | Seeking Alpha | ||
| 08.11. | Vor Bio's IgA nephropathy drug shows 55% reduction in proteinuria | 3 | Investing.com | ||
| 08.11. | Vor Bio: Medikament gegen IgA-Nephropathie reduziert Proteinurie um 55 % | 10 | Investing.com Deutsch | ||
| 08.11. | Vor Biopharma: Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China | 168 | GlobeNewswire (Europe) | Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated... ► Artikel lesen | |
| 03.11. | Vor Biopharma Appoints Jeremy Sokolove As New Chief Medical Officer | 3 | RTTNews | ||
| 03.11. | Vor Bio appoints Jeremy Sokolove as chief medical officer | 2 | Investing.com | ||
| 31.10. | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 29.10. | Vor Biopharma: Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data | 167 | GlobeNewswire (Europe) | Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved =2-point Myasthenia Gravis Activities... ► Artikel lesen |
1 2 3 4 5 Weiter >>
95 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 2,100 | -2,78 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,009 | +17,95 % | SOL Global Investments Corp.: SOL Global Announces Share Consolidation | Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL" or the "Company") announces that a majority vote by its Board of Directors... ► Artikel lesen | |
| TRINITY BIOTECH | 1,060 | -0,93 % | Trinity Biotech plc: Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation | DUBLIN, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,950 | -3,46 % | Fate Therapeutics, Inc.: Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs | ||
| ARCTURUS THERAPEUTICS | 7,460 | -0,80 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,370 | -2,84 % | Ovid Therapeutics: Aktionäre genehmigen Erhöhung der genehmigten Aktien und weitere Anträge | ||
| EQUILLIUM | 1,222 | +11,50 % | Equillium, Inc.: Equillium Announces Leadership and Corporate Updates | LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics... ► Artikel lesen | |
| GENERATION BIO | 5,460 | +0,55 % | Generation Bio Co.: Generation Bio Announces CEO Transition | • Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE,... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 10,840 | -0,82 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | ||
| REGENCELL BIOSCIENCE | 16,600 | -1,48 % | This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock) | ||
| CABALETTA BIO | 2,365 | +0,21 % | Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update | Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient... ► Artikel lesen | |
| LONGEVERON | 0,603 | -3,91 % | Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy | The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved... ► Artikel lesen | |
| PROKIDNEY | 2,210 | -0,45 % | ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates | Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of... ► Artikel lesen | |
| ATHIRA PHARMA | 3,870 | -2,03 % | Athira Pharma, Inc.: Athira Pharma Announces Reverse Stock Split | BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore... ► Artikel lesen | |
| BOLT PROJECTS | 2,130 | -3,62 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,390 (+3,22 %) liegt der Kurs bei 12,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.